Literature DB >> 2905149

Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway.

A N Nicholson1, N A Wright, M B Zetlein, D Currie, D G McDevitt.   

Abstract

1. Effects of the beta-adrenoceptor antagonists, propranolol (40, 80 and 160 mg) and atenolol (50 and 100 mg) on the electroencephalogram and on body sway, were studied in 12 healthy male subjects. The study was double-blind, and included two placebos and an active control, oxazepam (15 mg). Medication was ingested at 11.00 h, and assessments were made before, and at 2 h and 4 h after ingestion. 2. All doses of both beta-adrenoceptor antagonists modified the electroencephalogram, and the changes reported were statistically significant at probability levels of less than 5%. The circadian rise in alpha activity was reduced by both beta-adrenoceptor antagonists as well as by oxazepam. Atenolol also decreased beta activity. 3. Body sway was modified by atenolol and oxazepam (P less than 0.05). The increase with oxazepam was most marked in the low frequency component (0.05-2.25 Hz) of the spectrum, while atenolol modified only the component of higher frequency (2.25-4.0 Hz). 4. These observations suggest that propranolol and atenolol have a sedative effect, and that hydrophilic antagonists are unlikely to be free of central activity. The changes in body sway could imply that peripheral mechanisms may be modified at least with atenolol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905149      PMCID: PMC1386520          DOI: 10.1111/j.1365-2125.1988.tb03379.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood.

Authors:  D Currie; R V Lewis; D G McDevitt; A N Nicholson; N A Wright
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

2.  A multidimensional concept for measuring CNS effects of beta-adrenoceptor blocking agents in human pharmacology.

Authors:  W Wagner; H Ott; W M Herrmann; R J McDonald; B Berzewski
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1981-01

3.  Effect on postural sway of various benzodiazepine tranquillizers.

Authors:  A Patat; P Foulhoux
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

4.  The use of the EEG for assessment of vigilance changes caused by beta-blockers.

Authors:  M Matousek; A Hjalmarson; J Koch; I Petersén
Journal:  Neuropsychobiology       Date:  1984       Impact factor: 2.328

5.  Propranolol in the treatment of narcolepsy.

Authors:  A Kales; C R Soldatos; R Cadieux; E O Bixler; T L Tan; M B Scharf
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

6.  Central mechanisms of clonidine and propranolol in man. Quantitative Pharmaco-EEG with antihypertensive compounds.

Authors:  T M Itil; K Z Itil
Journal:  Chest       Date:  1983-02       Impact factor: 9.410

7.  Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect.

Authors:  F M Gengo; L Huntoon; W B McHugh
Journal:  Arch Intern Med       Date:  1987-01

8.  Central effects of beta-adrenoceptor antagonists.

Authors:  S A Salem; D G McDevitt
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

9.  Propranolol: long-term treatment in narcolepsy-cataplexy.

Authors:  K Meier-Ewert; K Matsubayashi; L Benter
Journal:  Sleep       Date:  1985       Impact factor: 5.849

10.  Beta-adrenoceptor antagonists: studies on behaviour (delayed differentiation) in the monkey (Macaca mulatta).

Authors:  A N Nicholson; C M Wright
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

View more
  16 in total

1.  Cognitive impairment associated with beta-blockade in the elderly.

Authors:  T K Rogers; C E Bowman
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

Review 2.  The effects of fall-risk-increasing drugs on postural control: a literature review.

Authors:  Maartje H de Groot; Jos P C M van Campen; Marije A Moek; Linda R Tulner; Jos H Beijnen; Claudine J C Lamoth
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

3.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood.

Authors:  D Currie; R V Lewis; D G McDevitt; A N Nicholson; N A Wright
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

Review 5.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

6.  Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy.

Authors:  C Dahlöf; E Dimenäs; B Olofsson
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

7.  A study of the antiulcer mechanisms of propranolol in rats.

Authors:  S K Kaan; C H Cho
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

8.  Central effects of the angiotensin-converting enzyme inhibitor, captopril. II. Electroencephalogram and body sway.

Authors:  A N Nicholson; N A Wright; M B Zetlein; D Currie; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

9.  Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood.

Authors:  D Currie; R V Lewis; D G McDevitt; A N Nicholson; N A Wright
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

10.  Central effects of the calcium antagonist, nifedipine.

Authors:  D G McDevitt; D Currie; A N Nicholson; N A Wright; M B Zetlein
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.